Portfolio

Circadian Therapeutics is developing a portfolio of products to treat diseases related to treat circadian rhythm disorders.

We are rapidly moving CT-1500, our initial product for Non-24, towards NDA/MAA.

We are researching other pathways and validating efficacy of lead candidate drugs in non-human disease models, and will license these products as they become clinic-ready.

Overview of product development status
Portfolio Overview

Therapeutics that treat the causes, not just the symptoms

Contact

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

contact@circadiantherapeutics.com

+44 (0) 1865 546581

Registered Office

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

Registered No 10283353.

[et_social_follow icon_style="simple" icon_shape="circle" icons_location="left" col_number="3" custom_colors="true" bg_color="#ffffff" bg_color_hover="#ffffff" icon_color="#81ccf1" icon_color_hover="#81ccf1" outer_color="dark"]

PRIVACY POLICY

© Circadian Therapeutics 2018.
All rights reserved.

Website Design by Brand Cooke